We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cutaneous Iontophoresis of Treprostinil in Systemic Sclerosis: A Proof-of-Concept Study.
- Authors
Roustit, M; Gaillard‐Bigot, F; Blaise, S; Stanke‐Labesque, F; Cracowski, C; Seinturier, C; Jourdil, J‐F; Imbert, B; Carpentier, P H; Cracowski, J‐L
- Abstract
Ischemic digital ulcer (DU) is a serious complication of systemic sclerosis (SSc). Intravenous prostanoids are the only approved treatment for active DUs, but they induce dose-limiting side effects and require hospitalization. Our objective was to evaluate the effect of iontophoresis (a noninvasive drug delivery method) of treprostinil in SSc patients. Three studies were conducted: a pharmacokinetic study in 12 healthy volunteers showed that peak dermal concentration was reached at 2 hours, whereas plasma treprostinil was undetected. Then, a placebo-controlled, double-blind incremental dose study assessed the effect of treprostinil on digital skin blood flow in 22 healthy subjects. The effect of the highest dose was then compared with that of placebo in 12 SSc patients. Treprostinil significantly increased skin blood flow in healthy subjects (P = 0.006) and in SSc patients (P = 0.023). In conclusion, digital iontophoresis of treprostinil is feasible, is well tolerated, and increases digital skin perfusion. It could be tested as a treatment for SSc-related DUs.
- Subjects
SYSTEMIC scleroderma; IONTOPHORESIS; PROSTANOIDS; PHARMACOKINETICS; BLOOD flow; VASODILATION
- Publication
Clinical Pharmacology & Therapeutics, 2014, Vol 95, Issue 4, p439
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2013.255